Does EBV reactivation drive B-cell activation and autoantibody production?

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that establishes a complex, lifelong relationship with the host immune system, specifically targeting the B-cell lineage. While often dormant, its reactivation is increasingly recognized as a potent trigger for immune dysregulation and the development of autoimmune pathologies.

Clinical and mechanistic evidence

The interaction between EBV and B cells is characterized by specific molecular entry points and sophisticated persistence strategies:

• Viral Entry and Persistence: EBV utilizes its envelope glycoprotein gp350 to bind to the CD21 receptor on B cells, facilitating entry via HLA class II molecules. Once inside, it establishes a reservoir in resting memory B cells (Latency 0/I), effectively evading cytotoxic T-lymphocyte detection through epigenetic silencing of viral proteins.
• B-Cell Activation: Reactivation into the lytic cycle often occurs during B-cell differentiation into plasma cells. Viral proteins, notably LMP1, function as functional mimics of CD40 signaling, providing constitutive survival signals that drive B-cell proliferation and the upregulation of Activation-Induced Cytidine Deaminase (AID), which is essential for class-switch recombination.
• Autoantibody Production: In clinical cohorts (e.g., SLE, Rheumatoid Arthritis, and Multiple Sclerosis), elevated titers of EBV Early Antigen (EA) IgG—a marker of active replication—strongly correlate with increased autoantibody levels, such as Rheumatoid Factor and anti-CCP.

Drivers of autoimmunity

Two primary mechanisms bridge the gap between viral reactivation and systemic autoimmunity:

• Molecular Mimicry: High-affinity antibodies targeting EBV proteins can cross-react with host tissues. For example, anti-EBNA1 antibodies exhibit significant cross-reactivity with CNS antigens (like GlialCAM) in Multiple Sclerosis and various nuclear antigens in SLE, leading to epitope spreading.
• Bystander Stimulation: The lytic cycle creates a localized "cytokine storm" (high IL-6 levels) and provides non-specific co-stimulatory signals. This pro-inflammatory milieu lowers the threshold for the activation of pre-existing, dormant autoreactive B-cell clones that would otherwise remain in check.

Bottom line

EBV establishes lifelong latency in memory B cells; its reactivation drives B-cell hyperactivity and autoantibody production through a combination of molecular mimicry and bystander activation, serving as a critical environmental catalyst for several autoimmune diseases.